KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Accumulated Expenses (2016 - 2025)

CRISPR Therapeutics AG's Accumulated Expenses history spans 11 years, with the latest figure at $89.4 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 384.77% year-over-year to $89.4 million; the TTM value through Dec 2025 reached $89.4 million, up 384.77%, while the annual FY2025 figure was $89.4 million, 384.77% up from the prior year.
  • Accumulated Expenses for Q4 2025 was $89.4 million at CRISPR Therapeutics AG, up from $84.2 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $91.9 million in Q2 2024 and bottomed at $7.5 million in Q1 2024.
  • The 5-year median for Accumulated Expenses is $69.9 million (2021), against an average of $58.3 million.
  • The largest annual shift saw Accumulated Expenses tumbled 91.26% in 2024 before it skyrocketed 1031.22% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $23.7 million in 2021, then surged by 228.31% to $77.7 million in 2022, then tumbled by 77.67% to $17.3 million in 2023, then grew by 6.32% to $18.4 million in 2024, then surged by 384.77% to $89.4 million in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Accumulated Expenses are $89.4 million (Q4 2025), $84.2 million (Q3 2025), and $73.7 million (Q2 2025).